HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Proposes Coal Tar/Menthol Addition To OTC Dandruff Monograph

This article was originally published in The Rose Sheet

Executive Summary

The final monograph for OTC dandruff, seborrheic dermatitis and psoriasis drug products would be amended to include a specific combination of coal tar and menthol under a proposed rule published by FDA in the Federal Register Dec. 9

You may also be interested in...



FDA Will Consider Triclosan For OTC Acne Monograph Inclusion

FDA is seeking data on use of triclosan in topical acne treatment products, the agency announced in a Dec. 5 Federal Register 1notice

Energizer Grows Personal Care With Acquisition Of Leading Sun-Care Brands

Energizer Holdings will gain Banana Boat and Hawaiian Tropic - the No. 2- and No. 4-selling sun- care brands, respectively - through its $1.9 billion purchase of Playtex Products, the companies announce July 12

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel